Choosing a Singapore Entry Structure: Subsidiary, Independent Holder or Distributor

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

A Chinese manufacturer entering Singapore has three structural options: establish its own Singapore subsidiary and act as Registrant and licence holder itself; appoint an independent third-party licence-holding organisation such as GRZAN as Registrant; or let the local distributor act as Registrant. The three differ markedly on control, speed to market, fixed cost and exit flexibility. The choice should follow the company’s market stage and the size of the product portfolio rather than a single template applied to every case, because the structure determines who holds the registration, who holds the dealer’s licence and who controls the customer relationship for as long as the product stays on the Singapore register.

  • Three viable structures. Own subsidiary, independent licence holder or distributor, each lawful and each with a different risk profile.
  • Control sits with the Registrant. The entity named on the registration controls the market access switch, not the manufacturer by default.
  • Speed and cost trade off. A subsidiary is the slowest and most expensive to stand up; an independent holder is the fastest.
  • A local entity is a technical necessity. SHARE requires CorpPass, and CorpPass is issued to Singapore-registered entities.
  • Structure can evolve. A transfer under GN-24 at SGD 880 and 40 working days allows a later move to a subsidiary.
  • Vigilance cannot be outsourced away. Each involved party retains its own reporting obligation.

2. Legal basis

GN-15 R15, issued in October 2026, defines the Registrant as the Singapore local entity that applies for and obtains the registration, supported by a letter of authorisation in the Annex 1 format. GN-02 R8, effective 1 April 2026, requires import, wholesale and manufacture to be covered by the corresponding dealer’s licence. Access to the filing systems runs through SHARE and CorpPass, which are available to Singapore-registered entities. A change of Registrant is handled under GN-24 R2 at SGD 880 and 40 working days, and registrations are maintained through the annual retention fee under section 12 of GN-15 R15 at SGD 39 for Class B, SGD 67 for Class C and SGD 134 for Class D.

Registrant systemGN-15 R15 (October 2026): the Registrant is the Singapore local entity that applies for and obtains the registration
AuthorisationGN-15 R15, Annex 1 letter of authorisation
LicensingGN-02 R8 (effective 1 April 2026): import, wholesale and manufacture each require the corresponding licence
System accessSHARE and CorpPass: a Singapore-registered entity is required
Change of holderGN-24 R2: SGD 880 / 40 working days
Registration maintenanceGN-15 R15, section 12: annual retention fee of SGD 39 for Class B, SGD 67 for Class C, SGD 134 for Class D

The comparison below sets out how the three structures behave against the dimensions that usually decide the question.

Dimension1. Own subsidiary2. Independent licence holder3. Distributor holds
Speed to marketSlow: entity, CorpPass and QMS firstFast: can start immediatelyFast
Fixed costHigh: entity upkeep, staff, QMS, licence at SGD 1,110 per year per licenceMedium: annual service feeLow: usually bundled into distribution terms
Control of the registrationFully in-houseManufacturer keeps authorisation and withdrawal rightsBound to the distribution relationship
Flexibility to change channelHighHigh: certificate stays, channel changesLow: changing channel means changing the certificate
Regulatory capabilityMust be built in-houseProvided by the licence holderDepends on the distributor
Best fitSingapore as a strategic market with a broad portfolioThe default choice for most Chinese manufacturersA single distributor or a short market test

3. Expert insights

CorpPass is a technical constraint on structure and has to be considered first. SHARE requires CorpPass, and CorpPass is issued to Singapore-registered entities. An offshore manufacturer therefore cannot apply directly, as a matter of system design rather than policy preference. The question is not whether a local entity is needed, since one always is, but whose subsidiary that entity will be. That reframing is useful in board discussions, because it moves the debate away from whether to incorporate and towards which party should own the incorporating vehicle and the registration that sits inside it.

The hidden costs of a subsidiary are routinely underestimated. Incorporation is only the beginning. Continuing costs include the annual filing and company secretarial service, local staff, QMS certification including the fees of an SAC-recognised body, dealer licences at SGD 1,110 per year per licence, the annual retention fee, and the operation of a vigilance system. For a Chinese manufacturer with only a handful of product lines, the arithmetic rarely works in favour of a subsidiary in the first years. The costs are fixed and recur whether or not the products sell, while the revenue that is meant to cover them is variable and arrives later.

The core value of independent holding is the decoupling of channel and registration. This is the point we return to repeatedly with clients across Southeast Asia. Letting the distributor hold the registration hands the market access switch to the channel partner. With an independent holder, changing distributor means changing a partner that holds the importer’s licence, while the certificate stays where it is. That flexibility is worth more in channel negotiations than the licence-holding service fee itself, because it changes the balance of power in every renewal conversation. A distributor that knows the registration cannot walk away negotiates differently from one that knows it can.

The structure can evolve in stages, and the initial contract should leave room for that. We do not recommend moving to the end state immediately. A common path is: in stage one, use an independent licence holder to reach the market quickly and validate demand; in stage two, once the market is established, incorporate a subsidiary if volumes justify it; in stage three, transfer the registration into the company’s own entity through GN-24 at SGD 880 and 40 working days. The evolution path should be anticipated in the initial agreement, with the conditions for transfer, the cooperation obligation and the cost allocation set out while the parties still have an incentive to agree.

Whatever the structure, the vigilance system cannot be outsourced cleanly. Even where a third party holds the registration, the product owner and each distributor retain their own adverse event reporting obligations; HSA’s position is that every involved party must submit its own report. Structure can be delegated, responsibility cannot. Manufacturers should therefore build their own reporting process and name a responsible person, even where the licence holder provides a vigilance service, because a report submitted by the holder does not discharge the product owner’s separate obligation.

4. Practical recommendations

  • Choose by portfolio size and strategic weight. Do not incorporate a subsidiary merely to look established; let volume and market commitment drive the decision.
  • Protect the decoupling of channel and registration. It is the foundation of long-term negotiating position in Singapore and the wider region.
  • Write the evolution path into the initial contract. Include the conditions for moving to an own entity and the cooperation obligations that go with it.
  • Retain vigilance responsibility in-house. Build a reporting process and name an owner regardless of who holds the registration.
  • Price the GN-24 transfer into the original decision. SGD 880 is the visible cost; the cooperation risk is the real one.

5. Verification checklist

  • □ The structure has been selected against portfolio size and strategic importance
  • □ The local entity’s Registrant and licence combination is confirmed
  • □ It is clear whether channel and registration are decoupled
  • □ The initial contract anticipates a later transfer of the registration
  • □ The vigilance system covers every Singapore entity involved
  • □ All annual holding costs have been calculated, including licence and retention fees

Regulatory information verified as of 26 October 2026. Source tiers: secondary (GN-15 R15, GN-02 R8, GN-24 R2).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail